Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)
Prognostic and Therapeutic Relevance of the 'Side Population' in Pancreatic Cancer
1 other identifier
observational
20
1 country
1
Brief Summary
In the current project we aim to study the oncological process of pancreatic cancer, from a perspective of the CSC-theory and in particular through the 'side population' (SP)-approach. The SP seems to be enriched for CSC and doesn't a priori exclude any CSC-subpopulation. After isolation from pancreatic cancer resection specimens, SP cells will be characterized by gene-expression profiling based on microarray analysis. We'll identify markers and pathways (with emphasis for stem cell and cancer -related ones) that are differentially expressed in SP versus the rest of tumour cells (the 'main population' or MP). In order to assess the prognostic relevance of the SP, we'll study these genes using the high-throughput Nanostring technology in about 200 snap-frozen PDAC resection specimens of patients from our prospective database. Finally, two monoclonal antibodies (mAB) will be tested as novel therapeutic agents in vivo (mouse model), wherein the choice of mAB will be based on prognostically relevant molecular targets and pathways obtained from the Nanostring results.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2008
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2008
CompletedFirst Submitted
Initial submission to the registry
July 7, 2009
CompletedFirst Posted
Study publicly available on registry
July 9, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2012
CompletedJuly 3, 2012
July 1, 2012
3.9 years
July 7, 2009
July 1, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Characterization of side population (SP) cells in pancreatic ductal adenocarcinoma (PDAC)
Study Arms (1)
SP in PDAC
Side population cells isolated from resection specimens obtained from patients with pancreatic cancer
Eligibility Criteria
SP cells will be identified through incubation with vital dye Hoechst 33342 of cell suspensions that are obtained from fresh human pancreatic cancer resection specimens.
You may qualify if:
- Resected pancreatic ductal adenocarcinoma (PDAC)
- Informed consent
You may not qualify if:
- Age \< 18years
- Pregnancy
- Pre-operative radiotherapy
- Pre-operative chemotherapy
- IPMT
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Leuven
Leuven, Vlaams-Brabant, 3000, Belgium
Related Publications (1)
Van den Broeck A, Gremeaux L, Topal B, Vankelecom H. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer. 2012 Aug 15;12:354. doi: 10.1186/1471-2407-12-354.
PMID: 22894607DERIVED
Biospecimen
Pancreatic cancer tissue specimen
MeSH Terms
Conditions
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Surgery
Study Record Dates
First Submitted
July 7, 2009
First Posted
July 9, 2009
Study Start
August 1, 2008
Primary Completion
July 1, 2012
Study Completion
July 1, 2012
Last Updated
July 3, 2012
Record last verified: 2012-07